TriReme Medical Selects OpenClinica Enterprise for Cardiovascular Clinical Trials

Share Article

Global producer of cardiovascular therapies looks to commercial open source software to support key clinical research.

TriReme selects OpenClinica clinical trial software
OpenClinica’s flexible model makes it easy for us obtain a regulatory compliant environment in which to collect and manage data for our pivotal clinical research

OpenClinica, LLC announces that TriReme Medical, a global producer of therapies for complex vascular disease, has selected the OpenClinica Enterprise Edition to enhance data collection and management in its clinical research.

TriReme Medical is a global company engaged in the design, manufacture, and distribution of advanced therapeutic solutions for the treatment of complex vascular disease. Their products include minimally invasive coronary and peripheral devices offering physicians new and differentiated tools to improve outcomes in complex peripheral and coronary interventions.

OpenClinica, LLC is the leading provider of commercial open source software for clinical trial electronic data capture and clinical data management. “OpenClinica’s flexible model makes it easy for us obtain a regulatory compliant environment in which to collect and manage data for our pivotal clinical research,” said Erin Tims, Associate Director, Clinical Affairs.

Coronary artery disease (CAD) is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. According to the American Heart Association, CAD affects over 13 million Americans and accounts for over 650,000 deaths annually.

“We are proud to be working with TriReme, a leading innovator in this critically important therapeutic area,” said Ben Baumann, OpenClinica’s Chief Operating Officer.

On May 23, 2012 TriReme announced FDA approval for its new Glider™ PTCA Catheter, the world’s first torqueable PTCA balloon catheter.

About TriReme Medical, Inc.

TriReme Medical, Inc. (TMI) is a privately held medical device company based in Pleasanton, California and Singapore. Founded in 2005, it is dedicated to the development and manufacturing of advanced therapeutic solutions for the treatment of complex vascular disease. Addressing specific unmet clinical needs, TMI is working with leading engineers and global thought leaders to offer physicians new and differentiated devices to improve outcomes in complex peripheral and coronary interventions.

About OpenClinica, LLC

OpenClinica, LLC enhances the productivity of clinical trials through commercial open source software. Trusted by hundreds of biopharmaceutical companies, contract research organizations, academic, and government organizations worldwide, OpenClinica’s software facilitates electronic data capture and data management, increasing the speed of collection and quality of data in clinical trials. OpenClinica supports HIPAA, 21 CFR Part 11, and other regulatory guidelines and is designed as a standards-based, extensible, and modular platform. For more information – including product downloads – visit http://www.openclinica.com or follow @OpenClinica on Twitter.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ben Baumann
Follow us on